WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010030931) OLIGONUCLEOTIDES TARGETING HUMAN ENDOGENOUS RETROVIRUS 9 (ERV-9) LONG TERMINAL REPEAT (LTR) AND METHODS OF USE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/030931    International Application No.:    PCT/US2009/056722
Publication Date: 18.03.2010 International Filing Date: 11.09.2009
IPC:
C12N 15/11 (2006.01), A61K 31/713 (2006.01)
Applicants: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES [US/US]; 6011 Executive Blvd., Suite 325 Msc 7660 Bethesda, MD 20892-7660 (US) (For All Designated States Except US).
XU, Lai [US/US]; (US) (For US Only).
ROSENBERG, Amy, S. [US/US]; (US) (For US Only).
ELKAHLOUN, Abdel [US/US]; (US) (For US Only).
CANDOTTI, Fabio [IT/US]; (US) (For US Only)
Inventors: XU, Lai; (US).
ROSENBERG, Amy, S.; (US).
ELKAHLOUN, Abdel; (US).
CANDOTTI, Fabio; (US)
Agent: GRAF, Susan, W.; (US)
Priority Data:
61/191,911 11.09.2008 US
Title (EN) OLIGONUCLEOTIDES TARGETING HUMAN ENDOGENOUS RETROVIRUS 9 (ERV-9) LONG TERMINAL REPEAT (LTR) AND METHODS OF USE
(FR) OLIGONUCLÉOTIDES CIBLANT LA LONGUE RÉPÉTITION TERMINALE (LTR) DU RÉTROVIRUS HUMAIN ENDOGÈNE 9 (ERV-9), ET PROCÉDÉS D'UTILISATION
Abstract: front page image
(EN)Described herein are oligonucleotides that target the human endogenous retrovirus-9 (ERV-9) long terminal repeat (LTR). The ERV-9 LTR oligonucleotides specifically hybridize with either the coding strand or non-coding strand of ERV-9 LTR. It is disclosed herein that ERV-9 LTR oligonucleotides inhibit the proliferation of cancer cells, including breast cancer, liver cancer, prostate cancer, fibrosarcoma and myeloid cancer cells. Also described herein are methods of treating a subject diagnosed with cancer comprising administering to the subject an ERV-9 LTR oligonucleotide. In some examples, the methods further comprise administering a second therapeutic agent, such as an antisense compound or a chemotherapeutic agent.
(FR)La présente invention concerne des oligonucléotides ciblant la longue répétition terminale (LTR) du rétrovirus humain endogène 9 (ERV-9). Ces oligonucléotides ERV-9 LTR s'hybrident spécifiquement, soit avec le brin codant, soit avec le brin non codant d'ERV-9 LTR. Selon l'invention, les oligonucléotides ERV-9 LTR inhibent la prolifération de cellules cancéreuses, et notamment du cancer du sein, du cancer du foie, du cancer de la prostate, de fibrosarcome, et des cellules cancéreuses myéloïdes. L'invention concerne également des procédés conçus pour traiter un sujet chez qui a été diagnostiqué un cancer, lesquels procédés comportent une administration d'un oligonucléotide ERV-9 LTR au sujet considéré. Dans certains cas, les procédés comprennent en outre l'administration d'un second agent thérapeutique tel qu'un composé antisens ou un qu'un agent chimiothérapique.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)